Pramlintide for the Treatment of Insulin-Requiring Diabetes Mellitus: Rationale and Review of Clinical Data

Authors: Kruger D.F.¹; Gloster M.A.²

Source: Drugs, Volume 64, Number 13, 2004 , pp. 1419-1432(14)

Buy & download fulltext article:

Price: $68.55 plus tax (Refund Policy)

Abstract:

Despite a number of incremental, beneficial improvements in diabetes mellitus therapy over the past few decades, the fundamental challenge of replicating the physiological entry into, and uptake of glucose from, the circulation remains unresolved.

Pramlintide is an analogue of the beta

-cell hormone amylin that simulates its important glucoregulatory actions. In humans, pramlintide slows gastric emptying and suppresses glucagon secretion during the prandial/postprandial period to slow and reduce the entry of glucose into the circulation. These actions, in conjunction with the glucose cellular uptake function of insulin, help normalise fluctuations in circulating glucose levels to a greater degree than is possible with insulin treatment alone. In clinical studies, pramlintide treatment as an adjunct to insulin decreased glycosylated haemoglobin levels (0.39–0.62%) with a concomitant weight loss (0.5–1.4kg) and no significant increase in severe hypoglycaemia.

Pramlintide treatment as a potential adjunct to insulin therapy is in late-stage development for patients with type 1 diabetes and insulin-using patients with type 2 diabetes.

Keywords: Diabetes mellitus, treatment; Pramlintide, general; Research and development

Document Type: Review article

Affiliations: 1: 1 Henry Ford Health System, Endocrinology and Metabolism, Detroit, Michigan, USA 2: 2 Amylin Pharmaceuticals Inc., San Diego, California, USA

Publication date: 2004-01-01